MX2012002677A - Forma farmaceutica oral, que consta de al menos un agente activo, sustancias auxiliares de formulacion y particulas magnetizables. - Google Patents
Forma farmaceutica oral, que consta de al menos un agente activo, sustancias auxiliares de formulacion y particulas magnetizables.Info
- Publication number
- MX2012002677A MX2012002677A MX2012002677A MX2012002677A MX2012002677A MX 2012002677 A MX2012002677 A MX 2012002677A MX 2012002677 A MX2012002677 A MX 2012002677A MX 2012002677 A MX2012002677 A MX 2012002677A MX 2012002677 A MX2012002677 A MX 2012002677A
- Authority
- MX
- Mexico
- Prior art keywords
- dosage form
- auxiliary substances
- magnetizable particles
- formulation auxiliary
- active agent
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2072—Pills, tablets, discs, rods characterised by shape, structure or size; Tablets with holes, special break lines or identification marks; Partially coated tablets; Disintegrating flat shaped forms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0002—Galenical forms characterised by the drug release technique; Application systems commanded by energy
- A61K9/0009—Galenical forms characterised by the drug release technique; Application systems commanded by energy involving or responsive to electricity, magnetism or acoustic waves; Galenical aspects of sonophoresis, iontophoresis, electroporation or electroosmosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/2095—Tabletting processes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2813—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/284—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone
- A61K9/2846—Poly(meth)acrylates
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/20—Pills, tablets, discs, rods
- A61K9/28—Dragees; Coated pills or tablets, e.g. with film or compression coating
- A61K9/2806—Coating materials
- A61K9/2833—Organic macromolecular compounds
- A61K9/286—Polysaccharides, e.g. gums; Cyclodextrin
- A61K9/2866—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4808—Preparations in capsules, e.g. of gelatin, of chocolate characterised by the form of the capsule or the structure of the filling; Capsules containing small tablets; Capsules with outer layer for immediate drug release
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4816—Wall or shell material
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4833—Encapsulating processes; Filling of capsules
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4883—Capsule finishing, e.g. dyeing, aromatising, polishing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
- A61K9/5094—Microcapsules containing magnetic carrier material, e.g. ferrite for drug targeting
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Epidemiology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Inorganic Chemistry (AREA)
- Nutrition Science (AREA)
- Physiology (AREA)
- Medicinal Preparation (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US23961309P | 2009-09-03 | 2009-09-03 | |
| DE102009029170 | 2009-09-03 | ||
| PCT/EP2010/062641 WO2011026808A1 (en) | 2009-09-03 | 2010-08-30 | Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2012002677A true MX2012002677A (es) | 2012-04-11 |
Family
ID=42984007
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2012002677A MX2012002677A (es) | 2009-09-03 | 2010-08-30 | Forma farmaceutica oral, que consta de al menos un agente activo, sustancias auxiliares de formulacion y particulas magnetizables. |
Country Status (13)
| Country | Link |
|---|---|
| US (1) | US9050256B2 (enExample) |
| EP (1) | EP2473095B1 (enExample) |
| JP (1) | JP5868319B2 (enExample) |
| KR (1) | KR101731130B1 (enExample) |
| CN (1) | CN102573612B (enExample) |
| BR (1) | BR112012004967B8 (enExample) |
| CA (1) | CA2772708C (enExample) |
| ES (1) | ES2528494T3 (enExample) |
| IL (1) | IL217897A (enExample) |
| MX (1) | MX2012002677A (enExample) |
| PL (1) | PL2473095T3 (enExample) |
| SI (1) | SI2473095T1 (enExample) |
| WO (1) | WO2011026808A1 (enExample) |
Families Citing this family (16)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CN103796626A (zh) * | 2011-09-14 | 2014-05-14 | 佛罗里达大学 | Smarttm固体口服剂型 |
| DE102011089334A1 (de) | 2011-12-21 | 2013-06-27 | Evonik Röhm Gmbh | Detektionssystem zur Erfassung magnetischer Objekte im menschlichen Organismus |
| US11667906B2 (en) * | 2014-11-24 | 2023-06-06 | Corning Incorporated | Magnetic microcarriers |
| US11024449B2 (en) * | 2017-06-06 | 2021-06-01 | Apple Inc. | Multipole elastomeric magnet with magnetic-field shunt |
| WO2019110321A1 (de) | 2017-12-04 | 2019-06-13 | Evonik Röhm Gmbh | Maskierung und nachfolgende sichtbarmachung von esr signalen mittels der kombination von zwei materialien |
| US10824822B2 (en) * | 2019-02-05 | 2020-11-03 | International Business Machines Corporation | Magnetic tracking for medicine management |
| US10679018B1 (en) | 2019-02-05 | 2020-06-09 | International Business Machines Corporation | Magnetic tracking for medicine management |
| JP7502741B2 (ja) * | 2019-09-26 | 2024-06-19 | スピンセンシングファクトリー株式会社 | 磁気マーカーおよび磁気マーカー検出システム |
| AU2021356684A1 (en) | 2020-10-09 | 2023-05-11 | The Trustees Of The University Of Pennsylvania | Compositions and methods for treatment of fabry disease |
| CN112360304A (zh) * | 2020-11-06 | 2021-02-12 | 炫丽建材江苏有限公司 | 一种适用于22度免拉手门板的自愈合封边工艺 |
| IL303390A (en) | 2020-12-03 | 2023-08-01 | Battelle Memorial Institute | Compositions of polymer nanoparticles and DNA nanostructures and methods for non-viral transport |
| WO2022216977A1 (en) | 2021-04-07 | 2022-10-13 | Batelle Memorial Institute | Rapid design, build, test, and learn technologies for identifying and using non-viral carriers |
| US20250250326A1 (en) | 2022-04-06 | 2025-08-07 | The Trustees Of The University Of Pennsylvania | Passive immunization with anti-aav neutralizing antibodies to prevent off-target transduction of intrathecally delivered aav vectors |
| CA3247109A1 (en) | 2022-04-06 | 2023-10-12 | The Trustees Of The University Of Pennsylvania | Compositions and treatment methods for metastatic breast cancer that is human epidermal growth factor receptor 2 positive and other cancers |
| WO2025072751A1 (en) | 2023-09-29 | 2025-04-03 | Battelle Memorial Institute | Polymer nanoparticle compositions for in vivo expression of polypeptides |
| AU2024393766A1 (en) | 2023-12-08 | 2026-06-18 | Battelle Memorial Institute | Use of dna origami nanostructures for molecular information based data storage systems |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| DE3723310A1 (de) * | 1987-07-15 | 1989-01-26 | John Urquhart | Pharmazeutisches praeparat und verfahren zu seiner herstellung |
| DE3740187A1 (de) | 1987-11-27 | 1989-06-08 | Urquhart John | Verfahren und vorrichtung zum ueberwachen und/oder kontrollieren und/oder registrieren und/oder anzeigen der einnahme von pharmazeutischen praeparaten |
| DE3940260A1 (de) | 1989-03-04 | 1990-09-13 | Werner Weitschies | Verfahren zur bestimmung des aufenthaltsortes und der bewegung von objekten durch ihre markierung als magnetisches moment |
| CN1056049C (zh) * | 1994-02-02 | 2000-09-06 | 湖南省商业科技研究所 | 一种磁疗食品的制备方法 |
| EP0928155A1 (de) | 1996-08-16 | 1999-07-14 | Roche Diagnostics GmbH | Kontrollsystem für die überwachung der regelmässigen einnahme eines medikamentes |
| JP2004331750A (ja) | 2003-05-02 | 2004-11-25 | Canon Inc | ポリヒドロキシアルカノエートを含有する磁性構造体及びその製造方法ならびにその用途 |
| EP1557151A1 (en) * | 2004-01-22 | 2005-07-27 | F. Hoffmann-La Roche Ag | Solid dosage form |
| CN100355454C (zh) | 2005-10-25 | 2007-12-19 | 南京工业大学 | 磁热疗用纳米磁粉－抗人肝癌单抗HAb18靶向药物 |
| EP1880716A1 (en) | 2006-07-19 | 2008-01-23 | Sandoz AG | Kit of parts comprising an acid labile and an acid resistant pharmaceutically active ingredient |
| DE102008033662A1 (de) | 2008-07-11 | 2010-01-14 | Technische Universität Ilmenau | Pharmakologische Darreichungsform und Vorrichtung und Verfahren zur kontinuierlichen Lokalisierung und Verfolgung des Auflösevorganges dieser |
-
2010
- 2010-08-30 JP JP2012527293A patent/JP5868319B2/ja not_active Expired - Fee Related
- 2010-08-30 WO PCT/EP2010/062641 patent/WO2011026808A1/en not_active Ceased
- 2010-08-30 US US13/390,353 patent/US9050256B2/en active Active
- 2010-08-30 SI SI201030850T patent/SI2473095T1/sl unknown
- 2010-08-30 KR KR1020127005600A patent/KR101731130B1/ko not_active Expired - Fee Related
- 2010-08-30 ES ES10747220.1T patent/ES2528494T3/es active Active
- 2010-08-30 PL PL10747220T patent/PL2473095T3/pl unknown
- 2010-08-30 CN CN201080039021.4A patent/CN102573612B/zh not_active Expired - Fee Related
- 2010-08-30 BR BR112012004967A patent/BR112012004967B8/pt not_active IP Right Cessation
- 2010-08-30 MX MX2012002677A patent/MX2012002677A/es active IP Right Grant
- 2010-08-30 CA CA2772708A patent/CA2772708C/en active Active
- 2010-08-30 EP EP10747220.1A patent/EP2473095B1/en active Active
-
2012
- 2012-02-02 IL IL217897A patent/IL217897A/en active IP Right Grant
Also Published As
| Publication number | Publication date |
|---|---|
| CA2772708C (en) | 2017-07-11 |
| KR101731130B1 (ko) | 2017-05-11 |
| BR112012004967B1 (pt) | 2021-05-11 |
| ES2528494T3 (es) | 2015-02-10 |
| SI2473095T1 (sl) | 2015-02-27 |
| US9050256B2 (en) | 2015-06-09 |
| IL217897A0 (en) | 2012-03-29 |
| IL217897A (en) | 2014-06-30 |
| US20120143039A1 (en) | 2012-06-07 |
| CN102573612B (zh) | 2015-07-08 |
| JP2013503831A (ja) | 2013-02-04 |
| JP5868319B2 (ja) | 2016-02-24 |
| EP2473095A1 (en) | 2012-07-11 |
| EP2473095B1 (en) | 2014-11-12 |
| CN102573612A (zh) | 2012-07-11 |
| CA2772708A1 (en) | 2011-03-10 |
| KR20120060210A (ko) | 2012-06-11 |
| BR112012004967B8 (pt) | 2022-07-05 |
| WO2011026808A1 (en) | 2011-03-10 |
| HK1168016A1 (en) | 2012-12-21 |
| WO2011026808A8 (en) | 2012-03-15 |
| BR112012004967A2 (pt) | 2016-04-05 |
| PL2473095T3 (pl) | 2015-04-30 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| WO2011026808A8 (en) | Oral dosage form, comprising at least one biologically active agent, formulation auxiliary substances and magnetizable particles | |
| EA201400972A1 (ru) | Лекарственные формы немедленного высвобождения с защитой от несанкционированного применения | |
| IN2014CN03307A (enExample) | ||
| MX2020000984A (es) | Una composicion farmaceutica que comprende nanoparticulas hibridas amorfas estables, de al menos un inhibidor de proteina quinasa y al menos un componente estabilizador polimerico y formador de matriz. | |
| MX2010009759A (es) | Dispositivo dosificador. | |
| FR2967674B1 (fr) | Derives d'heteroarylsulfonamides, leur preparation et leur application en therapeutique humaine | |
| WO2012121528A3 (en) | Magnetic nanocomposite specific for thyroid cancer and use thereof | |
| WO2012156317A3 (en) | Intranasal pharmaceutical dosage forms comprising naloxone | |
| IL216135A (en) | Preparations through the skin that include complexes of active substance with calcium phosphate and methods of use | |
| IN2014MN02214A (enExample) | ||
| BRPI0721148B8 (pt) | nanopartículas magnéticas para aplicação em hipertermia, preparação destas e uso de construtos apresentando aplicação farmacológica | |
| BR112013028365A2 (pt) | "composição líquida compreendendo adi, composto compreendendo adi ligada covalentemente através de grupo de ligação a polietilenoglicol e uso de adi no preparo de composição para tratamento de câncer". | |
| CL2012003012A1 (es) | Composicion farmaceutica oral de liberacion prolongada que comprenden a) al menos un material de liberacion prolongada y b) hidromorfona o una sal y naloxona o una sal en una relacion 2:1 a 1:3; metodo de preparacion. | |
| WO2012098562A3 (en) | Liquid oral compositions of lanthanum salts | |
| EP4527855A3 (en) | Stable igg4 based binding agent formulations | |
| CL2012003168A1 (es) | Composicion farmaceutica que comprende una solucion acuosa de minociclina y un cation divalente o trivalente en una proporcion mayor de 2:1 con respecto a la minociclina; metodo de preparacion; kit y uso en el tratamiento de infecciones bacterianas. | |
| AR077225A1 (es) | Formulaciones inyectables que contienen asenapina y metodo de tratamiento que las utiliza | |
| BR112013003530A2 (pt) | ''produto farmacêutico, kit, uso e preparações'' | |
| CL2012001940A1 (es) | Composiciones que comprenden extractos de andrographis paniculata combinados con extractos de ginkgo biloba complejados con fosfolípidos; y su uso en la preparación de un medicamento para el tratamiento de alzheimer y esclerosis múltiple. | |
| EP2453747A4 (en) | IMIQUIMOD FORMULATIONS WITH LESS DOSE THICKNESS AND SHORT DOSAGE PLANS FOR THE TREATMENT OF WARTS IN THE GENITAL AND PERIANAL AREAS | |
| FR2958935B1 (fr) | Derives d'heterocycles azotes, leur preparation et leur application en therapeutique humaine | |
| BR112012016736A2 (pt) | composição , formulação farmacêutica e uso da composição" | |
| PL2582359T3 (pl) | Stałe kompozycje w postaci proszków lub granulatów do podawania doustnego składników czynnych i sposoby ich otrzymywania | |
| IN2014MN02156A (enExample) | ||
| AR077483A1 (es) | Sal de citrato del 9e-15-(2-pirrolidin -1-il-etoxi)-7,12,25-trioxa-19-21,24-triaza-tetraciclo (18-3.1.1(2,5).1(14,18) hexacosa-1 (24),2,4,9,14,16,18 (26),20,22- nonaeno |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FG | Grant or registration |